Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer
- 1 April 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (4) , 443-450
- https://doi.org/10.1634/theoncologist.12-4-443
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the safety of using bevacizumab in clinical practice.Explain the benefit of adding bevacizumab to chemotherapy in colorectal cancer.Discuss mechanisms of targeting the VEGF/VEGFR pathway. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.comKeywords
This publication has 28 references indexed in Scilit:
- Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of PennsylvaniaCancer Investigation, 2005
- A case of reversible posterior leucoencephalopathy syndrome after rituximab infusionRheumatology, 2004
- Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignanciesAmerican Journal of Hematology, 2004
- Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced MelanomaClinical Cancer Research, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Angiogenic FactorsScience, 1987